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Objective: This study investigates the influence of foreign material and blood
aspirated from nonvascular structures on activation of coagulation, hemolysis, and
blood loss.
Methods: The series comprises 3 randomized groups (groups C, S, and SP) of 10
patients undergoing routine coronary artery bypass grafting with cardiopulmonary
bypass. In group C, the control group, all aspirated blood was returned into the
circulation. In group S suction blood was discarded, whereas group SP was
identical to group S, with surfaces coated with phosphorylcholine. Plasma concen-
trations of -thromboglobulin, thrombin generation, haptoglobin, and free hemo-
globin, as well as blood loss, were measured.
Results: A steady increase in free plasma hemoglobin, as well as an increased
generation of thrombin, was noticed in group C. Moreover, a close correlation (r 
0.916) between the generation of thrombin and its inhibition (thrombin-antithrom-
bin complexes) was observed. Platelets were clearly activated in group C and, to a
lesser extent, in group S. In contrast, platelet activation in group SP was negli-
gible, resulting in a 30% decrease in blood loss (P  .05).
Conclusions: Aspirated blood contaminated by tissue contact is the most important
activator of the coagulation system and the principal cause of hemolysis during
cardiopulmonary bypass. Contact with a foreign surface is not a main variable in the
procoagulant effect of bypass. Mimicking the outer cell membrane structure resulted
in decreased platelet activation and decreased blood loss.
During cardiopulmonary bypass (CPB), blood is diverted into anextracorporeal circulation. Those foreign surfaces exert a strongprocoagulant effect.1 Over the years, many improvements havebeen made to the components of the CPB circuit. Heparin coatingand, more recently, phosphorylcholine coating definitively reduceinflammatory response.2,3 The characteristic feature of biologic
membranes is their functional and compositional lipid asymmetry, which has been
described in several cell types. It is thought to stem from the requirement of biologic
membranes to have asymmetric protein distributions across the bilayer. In all of the
cells for which lipid compositional asymmetry has been described, negatively
charged phospholipids are found predominantly on the inner cytoplasmatic side of
the membrane, whereas the neutral zwitterionic phosphorylcholine containing an-
tithrombotic lipids predominate in the outer membrane leaflet. Negatively charged
phospholipids are thrombogenic. This membrane asymmetry may serve the biologic
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purpose in the maintenance of the delicate balance between
hemostasis and thrombosis. However, reduction in activa-
tion of the coagulation cascade and cell trauma is not
conclusive.3 This might be related to the fact that, in most
clinical studies, aspirated blood, which is recognized as one
of the most injurious components,4 is still reused. The
purpose of this study is to investigate the contribution of
aspirated blood versus foreign material in the activation of
the coagulation cascade and cell trauma.
Patients and Methods
Patients
Thirty patients were prospectively randomized into 1 of 3 groups.
All patients were subjected to elective coronary artery bypass
grafting. The sole exclusion criterion was an ejection fraction of
less than 40%. There were no statistical differences in demograph-
ics and operative data between groups (Table 1). The medical
ethical committee of the hospital approved the study, and written
informed consent was obtained from all patients.
In the control group (group C; n  10) CPB was performed in
a standard fashion, with recuperation of all suction blood into the
circulation. In the second group (group S; n  10) the same circuit
was used as in the control group, but aspirated blood collected
from the mediastinal cavities, pleural cavities, or both, was dis-
carded. The third group (group SP; n  10) was identical to
group 2, except for the coating of all foreign material with phos-
phorylcholine.
Operative Techniques
Before cannulation, porcine heparin (300 IU/kg; Roche Pharma-
ceuticals, Mannheim, Germany) was injected. Activated coagula-
tion time (kaolin ACT; Medtronic HemoTec, Inc, Englewood,
Colo) was kept above 400 seconds throughout CPB. CPB con-
sisted of a custom tubing pack made of polyvinyl chloride, an
arterial filter, a membrane oxygenator, and an open venous reser-
voir with separated cardiotomy reservoir (Dideco, Mirandola, It-
aly). Circuits were identical in the different groups, with the
exception of group SP, in which all surfaces in contact with
blood were coated with phosphorylcholine. The heart-lung ma-
chine (COBE Cardiovascular, Inc, Arvada, Colo) was primed with
a mixture of gelatin solution (Pasteur Merieux, Lyon, France),
mannitol (Baxter Healthcare Corporation, Deerfield, Ill), 2 million
KIU of aprotinin (Bayer AG, Leverkusen, Germany), and 5000 IU
of heparin (Roche, Brussels, Belgium). Total priming volume was
1300 mL. Esophageal temperature was lowered to 28°C. If possi-
ble, autologous blood was removed after induction, aiming at a
hematocrit level of 25% during CPB. During aortic crossclamping,
the aortic root was vented with a pressure-controlled roller pump.
Myocardial preservation during aortic crossclamping was obtained
with approximately 800 mL (600-900 mL) of crystalloid, ante-
grade, modified St Thomas’ Hospital cardioplegic solution.
Blood Sampling
Blood samples were taken after induction, at 15 minutes of CPB,
5 minutes after release of the aortic crossclamp, at the end of CPB,
20 minutes after CPB, and on postoperative days 1 and 2. Total
blood loss was documented at 4, 8, and 12 hours postoperatively.
Laboratory Assays
Serum concentrations of free hemoglobin and haptoglobin were
determined as markers of hemolysis by using immunonephelom-
etry5 on a BN nephelometer (Behringwerke AG, Marburg, Ger-
many) and expressed according to Instructional Faculty Consor-
tium Committee standards.6
The prothrombin fragment (F12), split off during conversion
of prothrombin to thrombin, was measured on citrated plasma by
using a quantitative enzyme-linked immunosorbent assay (ELISA;
Enzygnost F12 micro, Behring Diagnostics GmbH, Frankfurt,
Germany). The capture antibodies in this sandwich ELISA are
highly specific polyclonal antibodies raised in rabbits against a
synthetic peptide from the negatively charged region of the F12
fragment. Peroxidase-conjugated rabbit anti-human prothrombin
antibodies are used as the tagging antibody. The normal level,
determined in 24 healthy volunteers, is 1.16 0.39 nmol/L (range,
0.5-2.6 nmol/L; median, 1.1 nmol/L).
Thrombin-antithrombin complexes (TATs), reflecting throm-
bin generation followed by inhibition by antithrombin, were de-
termined on citrated plasma by means of ELISA (Enzygnost TAT
micro; Behring Diagnostics GmbH), according to the manufactur-
er’s instructions. This ELISA uses a polyclonal antibody specific
for neoantigenic determinants on thrombin as the capture antibody
and peroxidase-labeled polyclonal rabbit anti-human antithrombin
III as the tag antibody. The normal TAT level, determined in 24
healthy volunteers, is 4.07  2.33 ng/mL (range, 2-14.9 ng/mL;
median, 3.4 ng/mL).
-Thromboglobulin (-TG) released from -granules at plate-
let activation was recorded with commercially available ELISA
testing (Asserachrom -TG; Diagnostica Stago, Parsippany, NJ).
Normal values determined in 40 healthy donors ranged from 15 to
42 IU/mL (mean, 24.4 IU/mL).
TABLE 1. Demographic data and operative details of the studied groups*
Clinical parameter Group C (n  10), mean  SD Group S (n  10), mean  SD Group S  P (n  10), mean  SD
Age (y) 62 8 67 11 64 10
Female/male sex 4/6 1/9 0/10
Weight (kg) 81 14 77 9 83 13
No. of distal anastomoses 3.9 0.9 3.5 0.7 3.8 0.6
Extracorporeal time (min) 91 26 80 15 78 16
Aortic crossclamp time (min) 50 16 39 7 43 10
*All parameters were analyzed with the unpaired Student t test and showed no significant differences among the 3 study groups.
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Statistics
The overall differences among the 3 groups were analyzed with a
Kruskal-Wallis test. The comparison between each individual
group was done with a Mann-Whitney test corrected for repeated
comparisons. The sample points were related to the progress of the
operation and differed in each patient. Comparisons at each sample
point were therefore not considered relevant. Hence, the values
were treated individually for each patient, calculating the surface
under the curve representing the total release during CPB.
The correlation between the generation of thrombin (F12)
and its inhibition (TAT) was calculated with a Spearman R test.
Results
Coagulation
Lactic dehydrogenase. Lactic dehydrogenase (LDH)
levels increased in all groups on postoperative days 1 and 2
compared with baseline values (Figure 1). Mean total LDH
release was 296,318  137,924 U/L per procedure in group
C, 112,170  75,153 U/L per procedure in group S (P 
.005), and 136,212  91,602 U/L per procedure in group
SP (P  .01).
-Thromboglobulin. The concentration of -TG re-
mained stable during CPB in group SP, whereas an in-
crease over time was observed in groups S and C (Figure 1).
In all groups an increase of baseline values was noted at 20
minutes after CPB. Mean total release of -TG during CPB
was 3790  4103 IU/mL per CPB in the SP group,
18,870  20,479 IU/mL per CPB in group C (P  .016),
and 8040  3986 IU/mL per CPB in group S (P  .004).
Prothrombin fragment 12. In the control group an
important increase in F12 levels was noted during CPB
(Figure 2) from a mean baseline value of 1.9 1.8 to 5.0
3.0 g/L at the end of CPB, which further increased to
5.4  2.3 g/L at 20 minutes after CPB. In groups S and
SP the values remained stable during and after CPB.
Mean total F12 levels during CPB were 20,594  21,733
g/L per CPB in group C, 2534  2365 g/L per CPB in
group S (P  .001), and 2197  2095 g/L per CPB in
group SP (P  .001).
Thrombin-antithrombin complex. Mean values of
TAT complex decreased slightly in groups S and SP, from
25.3  42.7 nmol/L and 24.6  21.9 nmol/L to 8.6  8.1
nmol/L and 7.3  2.2 nmol/L at 15 minutes of bypass,
respectively (Figure 2). Subsequently, the values remained
stable during CPB and returned to baseline values at 20
minutes after CPB. This is in opposition to group C, in
which the mean baseline value of 56.9  85.8 nmol/L, after
a first decrease to 30.8  22.4 nmol/L, started to increase to
a value of 128.0  96.1 nmol/L at the end of CPB. Mean
total generation of TAT during CPB was 62,926  81,907
nmol/L per CPB in group C versus 4009 2958 nmol/L per
CPB in group S (P  .001) and 3925  1593 nmol/L per
CPB in group SP (P  .001). Moreover, close correlation
Figure 1. LDH and -TB levels. Pre, Blood samples taken after induction; PO1 and PO2, blood samples taken on
postoperative days 1 and 2; XC, blood samples taken after release of the aortic crossclamp; post, blood samples
taken 20 minutes after CPB.
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was established between levels of TAT and F12 (r 
0.916, P  .001) in group C (Figure 3).
Hemolysis
Free plasma hemoglobin. Whereas mean free plasma
hemoglobin levels remain stable in groups S and SP, there
is a steady increase from 9.9  4.3 mg/dL to 46.6  17.6
mg/dL at 20 minutes after CPB in group C (Figure 4). Mean
total generation of plasma free hemoglobin during the pro-
cedure was most pronounced in group C (353,800 
193,475 mg/dL per procedure) compared with that seen in
group S (70,140  56,462 mg/dL per procedure, P  .001)
and group SP (130,390  86,308 mg/dL per procedure,
P  .001).
Haptoglobin. Mean haptoglobin levels decreased in all
groups over time (Figure 4).
Blood Loss and Transfusions
In group S an average of 295  136 mL and in group SP
an average of 370  172 mL (P  not significant) of blood
was aspirated during CPB and discarded at the end of the
procedure. The hematocrit levels on postoperative day 1
were 30.6%  4.1% in group C, 29.9%  3.0% in group S,
and 32.8%  3.0% in group SP (P  .196).
The average blood loss during the first 4 hours postop-
eratively was 210 80 mL (P .05) in group SP, 326
170 mL in group C, and 338  223 mL in group S. Blood
losses between 4 and 8 hours and 8 and 12 hours postop-
eratively were not statistically significantly different be-
tween groups (Figure 5). Dividing the total population into
patients who lost more or less than 250 mL during the first
4 postoperative hours revealed duration of CPB (P  .001),
prolonged crossclamp time (P  .002), and number of
bypasses (P  .03) to be incremental risk factors for bleed-
ing. By using the same division with regard to the 3 groups,
a significant difference in reduced blood loss was found in
favor of group SP (P  .05, Table 2).
In none of the groups were blood products given during
CPB. In group S no blood products were given, whereas in
group SP 1 patient and in group C 4 patients received
packed red cells postoperatively (P  .05).
Discussion
Despite anticoagulation with high doses of heparin during
CPB, this procedure is associated with considerable activa-
tion of the coagulation system.1 The important rise in F12
and TAT levels obtained in our control group confirms the
procoagulant effect of CPB. In addition, significant activa-
tion of blood platelets and generation of hemolysis was
observed. After unclamping, most surgeons reinfuse blood
aspirated from the mediastinal and pleural cavities. Recir-
culation of suction blood is documented to decrease the
Figure 2. TAT and prothrombin 12 levels. Pre, Blood samples taken after induction; PO1 and PO2, blood samples
taken on postoperative days 1 and 2; XC, blood samples taken after release of the aortic crossclamp; end, blood
samples taken at the end of CPB; post, blood samples taken 20 minutes after CPB.
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mean arterial pressure,7 to activate the coagulation cas-
cade,8,9 and to generate hemolysis.8,10 As soon as blood
comes into contact with tissue factor, the coagulation cas-
cade is activated.11,12 As a result of surgical trauma, tissue
factor can be present in both mediastinal and pleural cavi-
ties. Therefore, blood recuperated from these cavities will
be activated, and thrombin will be generated, leading to
elevation of both TAT and F12. In our intervention groups
Figure 3. Correlation between TAT and F12 in group C.
Figure 4. Free plasma hemoglobin and haptoglobin levels. Pre, Blood samples taken after induction; PO1 and PO2,
blood samples taken on postoperative days 1 and 2; XC, blood samples taken after release of the aortic crossclamp;
end, blood samples taken at the end of CPB; post, blood samples taken 20 minutes after CPB.
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in which reinfusion of aspirated blood was omitted, almost
no rise in TAT and F12 levels was observed, clearly
suggesting aspirated blood to be the main cause of thrombin
generation. A discussion is ongoing whether heparin dosing
during CPB on the basis of ACT measurement is optimal or
whether heparin by itself is an adequate anticoagulant in this
setting.13-15 Several studies have shown a poor correlation
between ACT and plasma heparin levels, as measured with
an anti-Xa method.13 However, rapid point-of-care methods
to measure heparin levels are still in the process of valida-
tion. Therefore, in our study heparin dosing was still ad-
justed on the basis of the ACT. Despotis and colleagues14
described that a more effective suppression of the hemo-
static system in CPB may be obtained when heparin dosing
is based on heparin blood concentrations rather than on
ACT. In their study a negative correlation was found be-
tween F12 and TAT levels on the one hand and plasma
heparin concentrations, as measured with an anti-Xa
method, on the other hand. In contrast to this, the study of
Knudsen and coworkers15 clearly showed that high levels of
F12 may be generated during CPB, despite adequate
heparin anticoagulation, as measured with a plasma anti-Xa
method. In this study suction blood was also reinfused, and
the highest F12 levels were similar to those found in our
study shortly after unclamping. The high degree of compa-
rability of the F12 results of our control group and the
results reported by Knudsen and coworkers15 makes it un-
likely that the low F12 values in patients in whom no
aspirated blood was reinfused could be due to higher hep-
arin levels. Differences in the amount of aspirated blood
volume may account for the differences found in the liter-
ature. However, blood aspirated from cavities covered with
endothelium does not activate the coagulation.11
Destruction of red blood cells in contact with the peri-
cardium, pleural cavities, or both, was recognized in the
early days.16 In our control group, free plasma hemoglobin
started to increase after the release of the aortic crossclamp
simultaneously with a steady decrease in haptoglobin levels
over time. In a recent study in which aspirated blood was
kept separated until the end of CPB, a similar increase in
hemolysis was noticed after reinfusion of this aspirated
blood.10 Major hemolysis is caused by blood aspirated from
nonvascular cavities. This is most likely caused by shear
forces, negative pressure, and the blood-air interaction. The
effect of mechanical destruction (arterial roller pump) is
partially neutralized by means of rapid elimination of the
haptoglobin-hemopexin complexes at specific hepatic re-
ceptors. Hemolysis generation by means of the arterial roller
pump remains negligible during short-term cardiac surgery
Figure 5. Blood loss.
TABLE 2. Blood loss during the first 4 postoperative hours
<250 mL >250 mL Total
Group C 4 6 10
Group S 5 5 10
Group S  P 9 1 10*
Total 18 12 30
*P  .05.
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and was confirmed by low free plasma hemoglobin values
during CPB in both retainment groups.
In addition to high circulating levels of heparin, attempts
have been made to control activation of the coagulation
system by coating the foreign surface area of the CPB.
However, generation of TAT and F12 in most studies was
not conclusive.3
Phosphorylcholine coating mimics the characteristic fea-
ture of biologic membranes. In vitro experiments, in which
various phospholipid coatings were applied to surfaces,
showed a very high procoagulant activity of negatively
charged phospholipids. This is in contrast to the absence of
activation of phosphorylcholine-containing surfaces in co-
agulation tests.17,18 Blood platelets are not only essential for
coagulation but also interfere with white blood cell and
complement activation. Platelets were activated predomi-
nantly in group C by means of reinfusion of damaged and
activated platelets with aspirated blood. However, also in
group S, moderate platelet activation is noticed over time,
whereas absolutely no increase is observed in group SP.
Better platelet preservation in group SP is also reflected
by lower blood loss in the immediate postoperative period.
The difference between group S and group SP can be seen
as the representation of the damage caused by contact with
untreated foreign material. This finding is in agreement with
previous observations.2
No statistical differences regarding duration of CPB,
crossclamp time, and number of bypasses were observed
between groups. Nevertheless, a significantly higher num-
ber of patients lost less than 250 mL of blood in group SP.
In the population who lost more than 250 mL during the first
4 postoperative hours, there was a positive correlation with
the duration of CPB, crossclamp time, and number of by-
passes, which is in agreement with previous findings.19
Development of a dedicated venous reservoir makes it
possible to separate aspirated blood coming from different
sources. Blood from vascular structures can be safely re-
turned into the circulation, whereas highly activated blood
caused by contact with tissue factor should be kept sepa-
rated. Depending on the amount of blood loss, the latter can
be processed with a cell salvage system or discarded. More-
over, recent in vitro research also points out that generation
of fat emboli is negligible in groups without recuperation of
the mediastinal blood compared with that in a control
group.20
General Conclusion
Retainment of blood aspirated out of nonvascular structures
will significantly reduce morbidity of CPB. Blood activated
by means of tissue factor should be discarded or processed
with a cell salvage system. Phosphorylcholine coating is not
a main participant for control of the procoagulant effect of
CPB but results in decreased platelet activation and de-
creased blood loss.
Limitations of the Study
Because our study concerns a biologic system with rela-
tively large SDs in a limited number of patients, our data
should be interpreted with caution. Large randomized stud-
ies are necessary to investigate the influence of reinfusion of
aspirated blood on morbidity.
We thank Sorin-Biomedica, Mirandola, Italy, for providing
the phosphorylcholine-coated oxygenators, cannulas, and custom
packs.
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